Receptor for advanced glycation end‐products: Biological significance and imaging applications
WIREs Nanomedicine and Nanobiotechnology · 2024-01 · 16 (1)
DOI: 10.1002/wnan.1935 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 05.11.2023. Verfasst von Iwona T Dobrucki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA. Hauptthemen laut MEDLINE: Glycation End Products, Advanced, Diabetes Mellitus. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, Cancer Center at Illinois, Polish Ministry of Education and Science.
Abstract (Originalsprache)
The receptor for advanced glycation end‐products (RAGE or AGER) is a transmembrane, immunoglobulin‐like receptor that, due to its multiple isoform structures, binds to a diverse range of endo‐ and exogenous ligands. RAGE activation caused by the ligand binding initiates a cascade of complex pathways associated with producing free radicals, such as reactive nitric oxide and oxygen species, cell proliferation, and immunoinflammatory processes. The involvement of RAGE in the pathogenesis of disorders such as diabetes, inflammation, tumor progression, and endothelial dysfunction is dictated by the accumulation of advanced glycation end‐products (AGEs) at pathologic states leading to sustained RAGE upregulation. The involvement of RAGE and its ligands in numerous pathologies and diseases makes RAGE an interesting target for therapy focused on the modulation of both RAGE expression or activation and the production or exogenous administration of AGEs. Despite the known role that the RAGE/AGE axis plays in multiple disease states, there remains an urgent need to develop noninvasive, molecular imaging approaches that can accurately quantify RAGE levels in vivo that will aid in the validation of RAGE and its ligands as biomarkers and therapeutic targets. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Diagnostic Tools > Biosensing
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA.
- Department of Biomedical and Translational Sciences, Carle-Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Academy of Medical and Social Applied Sciences, Elblag, Poland.
- Cancer Center at Illinois, Urbana, Illinois, USA.
- Division of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, Gdansk, Poland.
ORCID-Profile: Iwona T Dobrucki, Angelo Miskalis, Michael Nelappana, Catherine Applegate, Marcin Wozniak, Leszek Kalinowski, Lawrence W Dobrucki
Förderung
- NIBIB NIH HHS
- Cancer Center at Illinois
- Polish Ministry of Education and Science
Zitieren
APA
Dobrucki, I. T., Miskalis, A., Nelappana, M., Applegate, C., Wozniak, M., Czerwinski, A., Kalinowski, L., & Dobrucki, L. W. (2024). Receptor for advanced glycation end‐products: Biological significance and imaging applications. WIREs Nanomedicine and Nanobiotechnology, 16(1). https://doi.org/10.1002/wnan.1935
Vancouver
Dobrucki IT, Miskalis A, Nelappana M, Applegate C, Wozniak M, Czerwinski A, et al. Receptor for advanced glycation end‐products: Biological significance and imaging applications. WIREs Nanomedicine and Nanobiotechnology. 2024;16(1). doi:10.1002/wnan.1935
BibTeX
@article{Dobrucki2024,
author = {Dobrucki, Iwona T and Miskalis, Angelo and Nelappana, Michael and Applegate, Catherine and Wozniak, Marcin and Czerwinski, Andrzej and Kalinowski, Leszek and Dobrucki, Lawrence W},
title = {Receptor for advanced glycation end‐products: Biological significance and imaging applications},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2024},
volume = {16},
number = {1},
doi = {10.1002/wnan.1935}
}
EUVIMED